Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $2,090,500.00 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Klein sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $83.62, for a total value of $2,090,500.00. Following the transaction, the chief executive officer owned 923,128 shares in the company, valued at $77,191,963.36. The trade was a 2.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lawrence Otto Klein also recently made the following trade(s):

• On Tuesday, September 15th, Lawrence Klein sold 2,452 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.71, for a total value of $234,680.92.
• On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00.

Oruka Therapeutics Stock Up 1.3%

Shares of Oruka Therapeutics stock traded up $1.10 during trading on Friday, reaching $84.52. The company’s stock had a trading volume of 581,494 shares, compared to its average volume of 969,009. Oruka Therapeutics, Inc. has a 12-month low of $19.04 and a 12-month high of $115.51. The business has a 50 day moving average price of $95.77 and a 200-day moving average price of $77.45.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. UBS Group upped their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Wedbush set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, September 24th. Finally, Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $128.91.

Institutional Trading of Oruka Therapeutics

Large investors have recently bought and sold shares of the company. Nykredit A S purchased a new stake in shares of Oruka Therapeutics in the 2nd quarter worth about $29,000. Orion Capital Management LLC purchased a new position in Oruka Therapeutics during the 2nd quarter valued at about $91,000. Natural Investments LLC purchased a new position in Oruka Therapeutics during the 2nd quarter valued at about $202,000. Caitong International Asset Management Co. Ltd purchased a new position in Oruka Therapeutics during the 4th quarter valued at about $67,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Oruka Therapeutics during the second quarter worth about $211,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.